Table 1.
Demographic characteristics, clinical symptoms, and laboratory examinations of patients with neurological manifestations diagnosed with DENV serotypes. (March 2014-July 2019)
| TOTAL | DENV-1 | DENV-2 | DENV-3 | DENV-4 | DENV-1/2/3 | |
|---|---|---|---|---|---|---|
| Age group % 1 m-3 m 4 m < 1 year 1y-4 years >4 years |
15.4 42.3 26.9 15.4 |
14.3 50 35.7 0 |
5 25 50 16.7 8.3 |
3 18.8 31.2 31.2 18.8 |
0 66.7 33.3 0 |
0 28.6 14.3 57.1 |
| Sex % Feminine Male |
40.4 59.6 |
42.3 57.7 |
58.3 41.7 |
11.1 88.9 |
100 0 |
42.9 57.1 |
| Fever % | 94.2 | 92.8 | 91.6 | 100 | 100 | 85.7 |
| Headache % | 40.9 | 14.3 | 0 | 62.5 | 0 | 40 |
| Vomit % | 46 | 57 | 25 | 68.8 | 33.3 | 14.3 |
| Myalgia % | 9.6 | 7.2 | 0 | 37.5 | 0 | 14.3 |
| Rash % | 13.5 | 7.2 | 8.3 | 12.5 | 33.3 | 28.6 |
| Hemoglobin* (g/dl) |
10.7 (6.9–13.7) |
10.5 (8.3–12.4) |
10.4 (6.9–13.2) |
11.2 (9–12.4) |
9.2 (6.5–11.1) |
12.2 (10.7–13.7) |
| Leucocytes* (x103/mm3) |
14.35 4–38.1 |
17.96 4–38.1 |
10.34 6.28–18.09 |
12.93 4.22–33.66 |
17.63 10.8–26.22 |
12.90 4.75–24.3 |
| Platelets* (x103/mm3) |
354.0 172–736 |
360.0 172–566 |
463.7 327–736 |
375.1 199–557 |
297.0 84–555 |
277.1 199 − 422 |
| CSF cells* (/mm3) |
79.7 (1–1640) |
45 (1–305) |
98.4 (1–760) |
184.3 (1–1640) |
46.3 (5–126) |
24.6 (8–70) |
| CSF glucose* (mg/dl) |
53 (38–88) |
55.4 (39–88) |
51.4 (40–65) |
53 (37–74) |
49.3 (44–54) |
56 (38–74) |
| CSF protein* (mg/dl) |
39.6 (6–237) |
40.4 (16–91) |
60 (6–237) |
37.9 (11–114) |
35.3 (9–77) |
24.4 (9–58) |
*Average, minimum and maximum value